In medical technology, boardrooms often set the pace long before a device reaches an operating theatre. Directors and advisors influence how companies handle clinical evidence, quality systems, supply constraints, and market access requirements that can determine whether a product advances or stalls. Governance also shapes how organizations respond when trials raise questions, when regulators ask for additional data, or when reimbursement criteria shift. In that environment, board service becomes a working layer of the device ecosystem, tying engineering decisions to risk, compliance, and adoption.
Board service in the medical device sector tends to sit at the intersection of technical direction and institutional accountability. Directors are expected to review development plans and ensure that decision-making stays aligned with safety, quality, and commercial constraints. In practice, that means pressure-testing assumptions around intended use, defining what “enough” evidence looks like for clinical claims, and ensuring the organization can demonstrate design controls and post-market obligations.
For executives with experience across research, commercialization, and clinical programs, board roles often center on two recurring tensions. The first involves the pace of iteration versus the stability required for regulated manufacturing. The second involves timing: what must be proven before a pivotal study, what can be learned in staged rollouts, and what must be documented to satisfy regulators, hospital procurement teams, and payers.
Kurt A. Dasse, Ph.D., has been associated with that governance layer through board seats and advisory roles across multiple device and biotech organizations. Public records and company announcements tie him to leadership and oversight roles in mechanical circulatory support, including work with Levitronix and GeNO, as well as board appointments at Makana Therapeutics.
Dasse’s board service has included companies and programs operating in cardiovascular devices, circulatory support, and adjacent specialties. In various biographies and career summaries, he is listed as serving on boards including Given Imaging, Afferent, Levitronix, Endovalve, GeNO, Flow Forward, Artio, Makana, VADovations, and Inspired Therapeutics. A specific example of a board-level appointment appears in a 2021 announcement from Makana Therapeutics, which named him to its board.
Board responsibilities in this segment typically revolve around three repeating agenda categories.
Device companies that operate in high-risk indications maintain structured risk-management systems that are often updated as clinical or manufacturing realities change. Board-level oversight commonly reviews hazard analyses, mitigations, complaint signals, and the operational plans needed to keep development milestones intact while meeting quality-system requirements.
Directors are frequently asked to interrogate endpoints, enrollment feasibility, and the adequacy of follow-up. A board may push for stronger evidence packages not only for regulators but also for hospital committees that evaluate adoption, especially in surgical, ICU, and pediatric contexts, where protocols, training, and long-term follow-up can influence demand.
Even when a device is technically functional, reimbursement policy can decide its scale. Boards review commercial assumptions, coding pathways, clinical utility narratives, and pricing strategies that are expected to match the realities of payer review and hospital budgeting.
Dasse’s professional timeline intersects with corporate transactions that illustrate why governance matters in this field. In 2011, Thoratec announced the acquisition of Levitronix’s medical business for $110 million in cash, plus potential milestone payments of up to $40 million, as reported by Reuters and reflected in the company’s press release. Those terms signal the kind of transition risk boards typically manage: continuity of design history files, post-acquisition manufacturing oversight, complaint-handling continuity, and product stewardship when assets move between organizations.
Similarly, GeNO announced in 2013 that Dasse, then serving as president and a member of the company’s board of managers, had been appointed chief executive officer. CEO appointments in regulated product environments often entail a governance dimension beyond standard corporate leadership, as the chief executive is tied to quality culture, clinical strategy, and a regulator-facing posture.
Beyond formal directorships, Dasse’s service has included advisory roles that operate as technical and governance extensions of the board. These roles often sit on technology advisory boards (TABs) and scientific advisory boards (SABs), as well as consortia focused on specific clinical gaps or regulatory pathways.
A governance challenge in pediatric and high-acuity device work is balancing the pace of innovation with safety requirements in small patient populations. In a published interview, Dasse discussed the structure of device commercialization and described barriers that can slow pediatric device programs, including funding and adoption constraints. While advisory bodies do not carry the fiduciary responsibilities of directors, they frequently influence design choices, protocol decisions, and the framing of clinical questions.
Advisory groups also function as “translation checkpoints.” They can help organizations decide whether a technical improvement changes a product’s risk profile enough to trigger revalidation, new clinical-evidence expectations, or an updated regulatory strategy. In areas such as mechanical circulatory support, small changes in materials, pump design, software controls, or alarms can shift the scope of validation. Advisory bodies often force early clarity on what must be locked down to prevent avoidable rework.
Device governance ultimately intersects with standards and policy because regulator expectations, consensus standards, and the evolving demands of clinical practice shape the lifecycle of a medical device. Directors and senior advisors frequently deal with the practical consequences of these frameworks: audit readiness, corrective and preventive action systems, and the discipline of documenting design changes in ways that remain defensible years later.
In Dasse’s case, public materials describing his work emphasize the long arc of bringing complex systems to market and the pressures that arise during development and scale-up. That arc typically includes recurring interactions with FDA-facing processes and ISO-aligned quality expectations, even when the details vary across product categories and intended uses. Governance shapes those interactions by deciding how aggressively a company sequences evidence, how it budgets for compliance infrastructure, and how it responds when timelines slip.
Seen from a distance, board service can look ceremonial. In the device sector, it rarely is. It is a mechanism for deciding what to prioritize, which risks to accept or reject, and how a company frames its technology in the language of regulators, clinicians, and payers. Dasse’s governance roles, spanning boards and advisory bodies related to cardiovascular and cardiopulmonary technologies, place him in the decision-making layer where standards and policy translate into concrete product pathways.
